I am sure you will hear more about this, but all these aspects condense into one key point: the importance of molecular profiling of the tumor. Today, we've talked about tissue profiling, which is the most common. However, we are increasingly using blood-based assays, which we refer to as "liquid biopsy". My colleague, Dr. Rolfo, has spearheaded the development and established guidelines for the use of it through IASLC.

Let me give you just one example — I know you will hear more about it later. We conducted a study where we utilized liquid biopsy for patients who received EGFR therapy. We found, using this blood-based assay to monitor therapy, that patients who cleared their EGFR mutation by the end of cycle two had much better overall survival than those who did not clear the assay for EGFR mutation. This could well be the direction we take in the future, and I'm sure you will hear much more about it later.